Immediate Impact
18 standout
Citing Papers
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Works of Céline Namour being referenced
Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
2022
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Céline Namour | 150 | 99 | 33 | 41 | 5 | 175 | |
| Sandra Assoun | 185 | 137 | 35 | 58 | 8 | 260 | |
| Kristen Labbe | 140 | 45 | 62 | 28 | 6 | 215 | |
| Pierre Van Mol | 95 | 88 | 52 | 26 | 10 | 218 | |
| Anna H. Wu | 66 | 110 | 15 | 44 | 7 | 272 | |
| Takayuki Shimamoto | 219 | 122 | 19 | 21 | 8 | 282 | |
| Benjamin Shum | 88 | 38 | 5 | 27 | 6 | 133 | |
| C. Codecà | 75 | 42 | 12 | 34 | 7 | 177 | |
| Goran Cabrilo | 42 | 50 | 17 | 63 | 6 | 151 | |
| S Mills | 85 | 49 | 13 | 25 | 7 | 263 | |
| Averdi Roezin | 115 | 29 | 20 | 38 | 4 | 224 |
All Works
Loading papers...